SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
4,606.00    20.00 (0.44%)
Bid:
4,604.00
Ask:
4,608.00
Spread: 4.00 (0.087%)
Market Cap: £16.79b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Annual Financial Report

23 Mar 2022 12:23

RNS Number : 7749F
Coca-Cola HBC AG
23 March 2022
 

Coca-Cola HBC AG

Publishes 2021 integrated annual report

'Boldly embracing the future'

 

 

Zug, Switzerland - 23 March 2022 - Coca-Cola HBC AG today published its 2021 Integrated Annual Report, Boldly embracing the future. The report highlights progress made on all aspects of business, governance and sustainability during 2021.

 

You can find our 2021 Integrated Annual Report, ("2021 Annual Report") in pdf format and structured electronic format here: https://www.coca-colahellenic.com/en/investor-relations/results-reports-presentations

 

A copy of the 2021 Annual Report has also been uploaded to the National Storage Mechanism in accordance with Listing Rule 9.6.1 and will shortly be available for inspection in unedited full text at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Printed copies of the 2021 Annual Report will be available on or around 20 April 2022 and can be requested by shareholders, free of charge, at https://www.coca-colahellenic.com/en/investor-relations/order-a-report

 

Coca‑Cola HBC Group

Investor and Analysts:

Joanna Kennedy

Head of Investor Relations

Tel: +44 7802 427505

 joanna.kennedy@cchellenic.com

 

 

 

Jemima Benstead

Investor Relations Manager

Tel: +44 7740 535130

jemima.benstead@cchellenic.com

 

 

Marios Matar

Investor Relations Manager

Tel: +30 697 444 3335

marios.matar@cchellenic.com

 

 

Media:

 

David Hart

Group Communication Director

Tel: +41 41 726 0143

 david.hart@cchellenic.com

 

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a growth-focused consumer packaged goods business and strategic bottling partner of The Coca-Cola Company. We create value for all our stakeholders by supporting the socio-economic development of the communities in which we operate and we believe building a more positive environmental impact is integral to our future growth. Together, we and our customers serve 715 million consumers across a broad geographic footprint of 29 countries on three continents. Our portfolio is one of the strongest, broadest and most flexible in the beverage industry, offering consumer-leading beverage brands in the sparkling, juice, water, sport, energy, plant-based, ready-to-drink tea, coffee, adult sparkling and premium spirits categories. These beverages include Coca-Cola, Coca-Cola Zero, Schweppes, Kinley, Costa, Valser, Romerquelle, Fanta, Sprite, Powerade, FuzeTea, Dobry, Cappy, Monster and Adez. We foster an open and inclusive work environment amongst our 36,000 employees and we are ranked among the top sustainability performers in ESG benchmarks such as the Dow Jones Sustainability Indices, CDP, MSCI ESG and FTSE4Good.

 

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE:CCH) and is listed on the Athens Exchange (ATHEX:EEE). For more information, please visit https://www.coca-colahellenic.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAADDAAEAEFA
Date   Source Headline
22nd May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:15 pmRNSDirector/PDMR Shareholding
11th May 20269:00 amRNSDirector Declaration
8th May 20263:15 pmRNSComposition of the Board Committees
8th May 20263:10 pmRNSResult of AGM
7th May 20267:00 amRNSStrong volume drives Q1 sales growth
20th Apr 20263:15 pmRNSDirector/PDMR Shareholding
14th Apr 202612:15 pmRNSNotice of Results
2nd Apr 20267:00 amRNSNotice of AGM, changes to the BoD, dividend dates
1st Apr 20269:15 amRNSTransfer of treasury shares & total voting rights
31st Mar 202611:00 amRNSPublication of Final Terms
27th Mar 20262:45 pmRNSDirector/PDMR Shareholding
27th Mar 20262:15 pmRNSDirector/PDMR Shareholding
26th Mar 20266:18 pmRNSPricing of Issue of Notes
26th Mar 20269:05 amRNSLaunch of Issue of Notes
25th Mar 20261:36 pmRNSPublication of a Prospectus
20th Mar 202611:00 amRNSAnnual Financial Report
19th Mar 20264:55 pmRNSDirector/PDMR Shareholding
19th Mar 20264:45 pmRNSDirector/PDMR Shareholding
18th Mar 20264:15 pmRNSDirector/PDMR Shareholding
18th Mar 202611:35 amRNSDirector/PDMR Shareholding
26th Feb 202611:30 amRNSDirector/PDMR Shareholding
25th Feb 20269:20 amRNSDirector/PDMR Shareholding
24th Feb 20264:55 pmRNSDirector/PDMR Shareholding
24th Feb 20264:50 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:35 pmRNSDirector/PDMR Shareholding
18th Feb 20264:50 pmRNSDirector/PDMR Shareholding
18th Feb 20264:45 pmRNSDirector/PDMR Shareholding
18th Feb 20264:00 pmRNSDirector/PDMR Shareholding
17th Feb 20263:35 pmRNSDirector/PDMR Shareholding
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20262:40 pmRNSDirector/PDMR Shareholding
16th Feb 20262:35 pmRNSDirector/PDMR Shareholding
13th Feb 202610:30 amRNSDirector/PDMR Shareholding
12th Feb 20263:45 pmRNSDirector/PDMR Shareholding
12th Feb 20261:15 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSStrong execution and financial performance in 2025
2nd Feb 202610:00 amRNSTransfer of treasury shares & total voting rights
19th Jan 20264:00 pmRNSDirector/PDMR Shareholding
19th Jan 20262:20 pmRNSResult of Extraordinary General Meeting
13th Jan 202611:00 amRNSNotice of Results
5th Jan 202610:00 amRNSDirector/PDMR Shareholding
23rd Dec 20252:45 pmRNSDirector/PDMR Shareholding
23rd Dec 20252:45 pmRNSDirector/PDMR Shareholding
22nd Dec 20252:15 pmRNSDirector/PDMR Shareholding
22nd Dec 20252:15 pmRNSDirector/PDMR Shareholding
18th Dec 20255:00 pmRNSDirector/PDMR Shareholding
18th Dec 20255:00 pmRNSDirector/PDMR Shareholding
18th Dec 20253:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.